Mirna Therapeutics, Inc. and Collaborators Publish New Data on miR-34 and its Role in Cancer Stem Cells

AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today the publication of new data in the journal Nature Medicine describing the role of the tumor suppressor miRNA, miR-34, in preventing cancer stem cell development. The published results reveal that miR-34 is commonly down-regulated in prostate cancer stem cells and that this down-regulation is essential for cancer stem cell viability. Systemic delivery of a miR-34 mimic inhibited tumor growth and metastasis in mice bearing prostate tumors. These new data support Mirna’s previous publication in the journal Cancer Research that showed that the systemic delivery of a miR-34 mimic can inhibit tumor growth in mouse models of lung cancer.